Hoth Therapeutics, Inc. - HOTH STOCK NEWS

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the company's pipeline, including proof-of-concept data for HT-ALZ, a novel Alzheimer's Disease therapeutic. The presentation is scheduled for the BIO International Convention in San Diego, California, from June 13-16, 2022. Hoth Therapeutics focuses on developing therapies for unmet medical needs, specifically targeting issues related to Alzheimer's, skin toxicities from cancer treatment, and other conditions. For more details, visit their website.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced significant development milestones for its cancer therapeutic, HT-KIT, following its receipt of Orphan Drug Designation from the FDA on March 11, 2022. HT-KIT targets the proto-oncogene cKIT and has shown promise in preclinical studies by inducing apoptosis in neoplastic mast cells. The company has completed manufacturing feasibility of HT-KIT in collaboration with WuXi STA and aims to hold a Pre-IND meeting with the FDA by the end of 2022, indicating progress towards advancing its clinical development.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced that the FDA has granted Orphan Drug designation to its new molecular entity, HT-KIT, for treating mastocytosis. This antisense oligonucleotide targets the cKIT proto-oncogene, showing promise in preclinical studies by inducing apoptosis in neoplastic mast cells. The Orphan Drug designation aids in development by providing tax credits, fee exemptions, and seven years of market exclusivity post-approval. HT-KIT aims to address rare but serious conditions like aggressive systemic mastocytosis, and its development is led by Hoth's scientific team.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has partnered with NUVISAN, a European CRO/CDMO, to manufacture clinical batches of its HT-001 topical drug for the upcoming CLEER-001 trial targeting skin toxicities in cancer therapy. This phase 2a randomized, placebo-controlled study will evaluate the efficacy, safety, and tolerability of HT-001 for patients undergoing EGFR inhibitor treatments at 14 sites in the United States. The collaboration aims to leverage NUVISAN's expertise in topical formulation to enhance the clinical development of this therapy.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced its submission of preclinical data on HT-ALZ for presentation at the Alzheimer's Association International Conference from July 31 - August 4, 2022, in San Diego. Dr. Carla Yuede, the lead researcher, will present findings from a sponsored research agreement with Washington University. This data is crucial in evaluating HT-ALZ's potential in treating Alzheimer's disease and aligns with Hoth's mission to address unmet medical needs across various indications, including neurological disorders.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) appointed Dr. John Cirrito and Dr. Carla Yuede to its Scientific Advisory Board to lead the development of HT-ALZ, an oral therapy targeting Alzheimer's disease. Dr. Cirrito, with extensive experience in Alzheimer's research, and Dr. Yuede, a behavioral neuroscience expert, will enhance the company's efforts in this critical area. CEO Robb Knie expressed optimism about their expertise driving the project forward. Hoth also has a sponsored research agreement with Washington University to further the preclinical studies for HT-ALZ.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced positive proof-of-concept data for its HT-ALZ therapeutic in an Alzheimer's disease mouse model. Conducted in collaboration with Washington University, the study showed a significant reduction of amyloid β (Aβ) in mice after treatment with HT-ALZ, indicating its potential to modify plaque formation. HT-ALZ is positioned for streamlined development under the 505(b)(2) regulatory pathway, accelerating its entry into efficacy trials. Future research will assess the impact of HT-ALZ on memory and cognitive function.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has submitted an Orphan Drug Designation Request to the FDA for HT-KIT to treat mastocytosis. HT-KIT targets the proto-oncogene cKIT, inducing apoptosis in neoplastic mast cells. The Orphan Drug Act offers benefits such as exclusive marketing rights, tax credits, and regulatory assistance, crucial for rare disease treatments. The company aims to leverage these advantages for the development of HT-KIT. Hoth's pipeline includes therapies for various conditions, highlighting its commitment to addressing unmet medical needs.

Hoth Therapeutics (NASDAQ: HOTH) has licensed its cannabinoid therapeutic HT-005 back to Zylö Therapeutics, focusing on treating lupus patients. This agreement allows Hoth to gain equity in Zylö and potential royalties while saving on future development costs, as Zylö will handle the subsequent stages of development. HT-005 has shown efficacy in animal studies, significantly reducing skin plaques associated with cutaneous lupus erythematosus. Hoth aims to develop therapies for various conditions, including atopic dermatitis and psoriasis.